Ergocalciferol 50000 unit
Pro Research Analysisby 
Searched over 200M research papers
Ergocalciferol 50,000 Units: Clinical Implications and Efficacy
Ergocalciferol in Type 1 Diabetes Management
Impact on Residual β-Cell Function and Partial Remission
Ergocalciferol, a form of vitamin D, has been studied for its potential benefits in managing Type 1 Diabetes (T1D). A randomized controlled trial investigated the effects of high-dose ergocalciferol (50,000 IU weekly for 2 months, then bi-weekly for 10 months) on residual β-cell function (RBCF) and partial clinical remission (PR) in youth with newly diagnosed T1D. The study found that ergocalciferol significantly reduced serum tumor necrosis factor α (TNF-α) and blunted the rise in glycated hemoglobin A1c (HbA1c) and insulin dose-adjusted A1c (IDAA1c) over 12 months, suggesting a protective effect on RBCF and PR Nwosu2021Nwosu2023.
Long-Term Effects on Pancreatic β-Cell Function
Further analysis revealed that ergocalciferol significantly slowed the decline in stimulated C-peptide levels, a marker of β-cell function, compared to placebo. This indicates that high-dose ergocalciferol may help preserve β-cell function in children and adolescents with newly diagnosed T1D, potentially prolonging the PR phase and improving clinical outcomes .
Ergocalciferol Dosing in Older Adults
Comparison with Cholecalciferol
A study comparing the efficacy of ergocalciferol (D2) and cholecalciferol (D3) in older adults found that both forms of vitamin D, administered either daily (1,600 IU) or monthly (50,000 IU), were effective in increasing serum 25-hydroxyvitamin D [25(OH)D] levels. However, D3 was slightly more effective than D2. Despite high compliance, about 20% of participants did not achieve optimal 25(OH)D levels, indicating significant individual variability in response to vitamin D supplementation .
Safety and Calcium Levels
The same study reported no significant changes in serum calcium, parathyroid hormone (PTH), bone-specific alkaline phosphatase, or urinary calcium levels, suggesting that high-dose ergocalciferol is safe for long-term use in older adults without causing hypercalcemia or other adverse effects .
Ergocalciferol in Insulin Sensitivity and Secretion
Effects on Healthy Adults with Low Vitamin D
A randomized controlled trial assessed the impact of high-dose ergocalciferol (50,000 IU weekly for 12 weeks) on insulin secretion and sensitivity in healthy adults with low baseline vitamin D levels. Despite significant increases in serum 25(OH)D, the study found no improvements in insulin response, insulin sensitivity, or other metabolic markers, indicating that ergocalciferol may not benefit glucose metabolism in this population .
Ergocalciferol in Critical Illness
Dose-Response Relationship
In critically ill patients with traumatic injuries, ergocalciferol therapy (50,000 IU weekly, twice weekly, or three times weekly) was evaluated for its effect on serum 25(OH)D levels. The study found that while ergocalciferol improved vitamin D levels, it was insufficient to consistently achieve normal serum concentrations. Additionally, there was a concerning trend of mild hypercalcemia in the highest dosage group, highlighting the need for careful monitoring in this population .
Conclusion
High-dose ergocalciferol (50,000 IU) shows promise in preserving β-cell function and prolonging partial remission in youth with newly diagnosed T1D. It is also effective in increasing serum 25(OH)D levels in older adults, though individual responses vary. However, its benefits on insulin sensitivity and secretion in healthy adults with low vitamin D are limited, and careful monitoring is required in critically ill patients to avoid hypercalcemia. Overall, ergocalciferol is a valuable tool in specific clinical scenarios, but its application must be tailored to individual patient needs and conditions.
Sources and full results
Most relevant research papers on this topic